Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.41 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8426900 | 0.97 | PDE3A (0.41) | PDE4DPDE3ASLC29A1LMNATHRB | |
| SCHEMBL9667470 | 0.89 | PDE3A (0.44) | PDE4DPDE3ASLC29A1LMNATHRB | |
| SCHEMBL1403455 | 0.85 | PDE3A (0.42) | PDE4DPDE3ASLC29A1LMNATHRB | |
| SCHEMBL9047407 | 0.85 | PDE3A (0.42) | PDE4DPDE3ASLC29A1LMNATHRB | |
| SCHEMBL31305353 | 0.85 | PDE3A (0.42) | PDE4DPDE3ASLC29A1LMNATHRB | |
| SCHEMBL9144955 | 0.85 | PDE3A (0.42) | PDE4DPDE3ASLC29A1LMNATHRB | |
| SCHEMBL4664909 | 0.83 | LMNA (0.44) | PDE4DPDE3ASLC29A1LMNATHRB | |
| SCHEMBL6060509 | 0.82 | PDE3A (0.45) | PDE4DPDE3ASLC29A1LMNATHRB | |
| SCHEMBL236109 | 0.82 | PDE3A (0.48) | PDE4DPDE3ASLC29A1LMNATHRB | |
| SCHEMBL331769 | 0.81 | LMNA (0.49) | PDE4DPDE3ASLC29A1LMNATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-8059687-A | — | — | None | — | — | JP | disclosed |
| US-20240239764-A1 | SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-07-18 | — | — | US | disclosed |
| US-20240150452-A1 | MULTIFUNCTIONAL PROTEIN MOLECULES COMPRISING DECORIN AND USE THEREOF | CATALENT PHARMA SOLUTIONS, LLC | 2024-05-09 | — | — | US | disclosed |
| US-20240083868-A1 | SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS | MEKANISTIC THERAPEUTICS, LLC | 2024-03-14 | — | — | US | disclosed |
| US-20240050415-A1 | DACLATASVIR FOR USE IN TREATING LUNG AND PROSTATE CANCER | HENRY FORD HEALTH SYSTEM (US) | 2024-02-15 | — | — | US | disclosed |
| US-11879009-B2 | Multifunctional protein molecules comprising decorin and use thereof | CATALENT PHARMA SOLUTIONS, LLC (US) | 2024-01-23 | — | — | US | disclosed |
| US-11673876-B2 | Substituted aminobenzyl heteroaryl compounds as EGFR and/or PI3K inhibitors | MEKANISTIC THERAPEUTICS LLC (US) | 2023-06-13 | — | — | US | disclosed |
| US-11607414-B2 | Small molecule inhibitors of EGFR and PI3K | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-03-21 | — | — | US | disclosed |
| CN-111100172-B | Cytosidine derivative and method for preparing capecitabine medicine from same | 中国科学院昆明植物研究所 | 2023-03-17 | — | — | CN | disclosed |
| US-20220275074-A1 | MULTIFUNCTIONAL PROTEIN MOLECULES COMPRISING DECORIN AND USE THEREOF | ARES CAPITAL CORPORATION, AS COLLATERAL AGENT | 2022-09-01 | — | — | US | disclosed |
| EP-2135867-A1 | Trans-9, 10-dehydroepothilone C and trans-9, 10-dehydroepothilone D, analogs thereof and methods of making the same | Kosan Biosciences Incorporated (US) | 2009-12-23 | — | — | EP | disclosed |
| EP-1562941-B1 | TRANS-9,10-DEHYDROEPOTHILONE C AND D, ANALOGS THEREOF AND METHOS OF MAKING THE SAME | KOSAN BIOSCIENCES INC (US) | 2009-12-23 | — | — | EP | disclosed |
| EP-2135868-A1 | TRANS-9, 10-DEHYDROEPOTHILONE C AND D, ANALOGS THEREOF AND METHODS OF MAKING THE SAME | Kosan Biosciences Incorporated (US) | 2009-12-23 | — | — | EP | disclosed |
| US-20090186927-A1 | TRANS-9,10-DEHYDROEPOTHILONE C AND D, ANALOGS THEREOF AND METHODS OF MAKING THE SAME | KOSAN BIOSCIENCES, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| US-20080095755-A1 | Methods and compositions for the treatment of cancer | QUINTESSENCE BIOSCIENCES, INC. (US) | 2008-04-24 | — | — | US | disclosed |
| EP-1562941-A2 | TRANS-9,10-DEHYDROEPOTHILONE C AND D, ANALOGS THEREOF AND METHOS OF MAKING THE SAME | Kosan Biosciences, Inc. (US) | 2005-08-17 | — | — | EP | disclosed |
| US-20040152708-A1 | Trans-9,10-dehydroepothilone C and D, analogs thereof and methods of making the same | KOSAN BIOSCIENCES, INC. | 2004-08-05 | — | — | US | disclosed |
| WO-2004043954-A2 | TRANS-9,10-DEHYDROEPOTHILONE C AND D, ANALOGS THEREOF AND METHOS OF MAKING THE SAME | KOSAN BIOSCIENCES INCORPORATED (US) | 2004-05-27 | — | — | WO | disclosed |
| EP-0698611-B1 | Process for N-acyl-5-fluorocytidine derivatives | HOFFMANN LA ROCHE (CH) | 1999-10-20 | — | — | EP | disclosed |
| JP-H0859687-A | PRODUCTION OF N4-ACYL-5'-DEOXY-5-FLUOROCYTIDINE DERIVATIVE | F HOFFMANN LA ROCHE AG | 1996-03-05 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11607414-B2 | Small molecule inhibitors of EGFR and PI3K | EGFR, ERBB2, ERBB3 | PDE4D 3216/4885PDE3A 3900/4885SLC29A1 1924/4885 |
| US-20240150452-A1 | MULTIFUNCTIONAL PROTEIN MOLECULES COMPRISING DECORIN AND USE THEREOF | CD2BP2, DSTN, SDCBP | PDE4D 2222/4885PDE3A 3810/4885SLC29A1 3807/4885 |
| US-11879009-B2 | Multifunctional protein molecules comprising decorin and use thereof | CD2BP2, DSTN, SDCBP | PDE4D 2222/4885PDE3A 3810/4885SLC29A1 3807/4885 |
| US-20240239764-A1 | SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS | EGFR, ERBB2, ERBB3 | PDE4D 3688/4885PDE3A 3734/4885SLC29A1 957/4885 |
| US-20220275074-A1 | MULTIFUNCTIONAL PROTEIN MOLECULES COMPRISING DECORIN AND USE THEREOF | CD2BP2, DSTN, SDCBP | PDE4D 2222/4885PDE3A 3810/4885SLC29A1 3807/4885 |
| US-11673876-B2 | Substituted aminobenzyl heteroaryl compounds as EGFR and/or PI3K inhibitors | EGFR, ERBB2, ERBB3 | PDE4D 3688/4885PDE3A 3734/4885SLC29A1 957/4885 |
| US-20040152708-A1 | Trans-9,10-dehydroepothilone C and D, analogs thereof and methods of making the same | TMSB10, TUBA1C, TUBB1 | PDE4D 2324/4885PDE3A 3394/4885SLC29A1 1459/4885 |
| US-20090186927-A1 | TRANS-9,10-DEHYDROEPOTHILONE C AND D, ANALOGS THEREOF AND METHODS OF MAKING THE SAME | TMSB10, TUBA1C, TUBB1 | PDE4D 2324/4885PDE3A 3394/4885SLC29A1 1459/4885 |
| US-20240083868-A1 | SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS | EGFR, ERBB2, ERBB3 | PDE4D 3688/4885PDE3A 3734/4885SLC29A1 957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.